IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?

Area of Science:

• Vaccinology
• Infectious Diseases
• Biotechnology

Background:

• Emerging infectious diseases, exemplified by SARS-CoV-2, necessitate rapid vaccine development.
• Platform technologies, adaptable for diverse pathogens, are vital for swift responses.
• Ongoing development is critical due to evolving viral variants.

Purpose of the Study:

• To discuss platform manufacturing techniques used for COVID-19 vaccine development.
• To gather regulatory perspectives on experiences and expectations regarding vaccine platforms.
• To identify lessons learned for enhancing future pandemic response.

Main Methods:

• Joint webinar organized by the International Alliance for Biological Standardization and the Coalition for Epidemic Preparedness Innovations.
• Discussion of manufacturing techniques for adaptable vaccine platforms.
• Input from regulatory authorities on platform technology utilization.

Main Results:

• Industry and regulators achieved unprecedented speed in vaccine development and licensing.
• Successful cooperation between industry and regulatory bodies was highlighted.
• The efficacy of platform technologies in responding to the COVID-19 pandemic was demonstrated.

Conclusions:

• Platform technologies are essential for rapid response to emerging infectious diseases.
• Continued investment in and development of platform technologies are necessary.
• Learning from the COVID-19 pandemic experience will improve future responses to novel pathogens ('disease X').